Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sarepta TherapeuticsLTS:0L35 -6.61%50 Cyclically Adjusted PS Ratio is 1.35 as of Jul. 29, 2026, which is 94% below its 10-year median of 23.86. GuruFocus rates LTS:0L35 with a GF Score™ of 50/100 and a GF Value™ of $128.79 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 537 Biotechnology companies, Sarepta Therapeutics ranks better than 81.01% on this metric.
The historical rank and industry rank for Sarepta Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:
LTS:0L35'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.17 Med: 23.86 Max: 98.48
Current: 1.36
During the past years, Sarepta Therapeutics's highest Cyclically Adjusted PS Ratio was 98.48. The lowest was 1.17. And the median was 23.86.
LTS:0L35's Cyclically Adjusted PS Ratio is ranked better than 81.01% of 537
companies
in the Biotechnology industry
Industry Median: 5.65
vs LTS:0L35: 1.36
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Sarepta Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2026 was $5.994. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $11.35 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Sarepta Therapeutics (LTS:0L35) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Sarepta Therapeutics Cyclically Adjusted PS Ratio Related Terms
Sarepta Therapeutics Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Sarepta Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics Cyclically Adjusted PS Ratio Chart
LTS:0L35 vs MPLT, ZYME, ABCL: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Sarepta Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sarepta Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's Cyclically Adjusted PS Ratio falls into.
Sarepta Therapeutics Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 1.35 mean?
Sarepta Therapeutics (LTS:0L35) has a Cyclically Adjusted PS Ratio of 1.35 as of Jul. 29, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sarepta Therapeutics and its competitors. This is 94% below median its historical median of 23.86. Over the past decade, Sarepta Therapeutics' Cyclically Adjusted PS Ratio has ranged from 1.17 to 98.48. According to the industry distribution chart, Sarepta Therapeutics ranks #102 out of 537 companies in the Biotechnology industry, placing it in the top 19%.
Is Sarepta Therapeutics' Cyclically Adjusted PS Ratio too high?
Sarepta Therapeutics' current Cyclically Adjusted PS Ratio of 1.35 is 94% below median its 10-year median of 23.86. Over the past 10 years, this metric has ranged from a low of 1.17 to a high of 98.48. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.65. Sarepta Therapeutics' value of 1.35 is 76.1% below this industry median. Based on the distribution chart, Sarepta Therapeutics ranks #102 out of 537 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sarepta Therapeutics has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Cyclically Adjusted PS Ratio compare to MPLT and ZYME?
According to the Biotechnology industry distribution chart, Sarepta Therapeutics ranks #102 out of 537 companies for Cyclically Adjusted PS Ratio. This places Sarepta Therapeutics in the top 19% of its industry — outperforming the majority of peers. The industry median Cyclically Adjusted PS Ratio is 5.65. Sarepta Therapeutics' value of 1.35 is 76.1% below this benchmark. Historically, Sarepta Therapeutics' own Cyclically Adjusted PS Ratio has ranged from 1.17 to 98.48 over the past decade. While the company's 10-year median is 23.86 vs. the industry median of 5.65, Sarepta Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.65, based on 537 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sarepta Therapeutics's current Cyclically Adjusted PS Ratio of 1.35 is 76.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sarepta Therapeutics and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sarepta Therapeutics's current Cyclically Adjusted PS Ratio is 1.35, which is 94% below median its own 10-year median of 23.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (LTS:0L35) is currently considered Possible Value Trap. The stock's GF Value™ is $128.79, compared to a current price of $15.33 — trading 88.1% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 1.35, which is 94% below median its 10-year median of 23.86 and 76.1% below the Biotechnology industry median of 5.65. Sarepta Therapeutics' overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Sarepta Therapeutics (LTS:0L35), the current Cyclically Adjusted PS Ratio is 1.35 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sarepta Therapeutics (LTS:0L35) Overvalued in 2026?
Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued.
The current stock price of $15.33 is trading 88.1% below its estimated GF Value™ of $128.79.
GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.
Key valuation signals for LTS:0L35:
Cyclically Adjusted PS Ratio: 1.35 (94% below median its 10-year median of 23.86)
GF Value™: $128.79 vs. price of $15.33 (88.1% below fair value)
Industry Position: 76.1% below the Biotechnology median (#102 of 537)
No single metric tells the full story. See the LTS:0L35 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
50GF Score
Get the complete analysis for LTS:0L35
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0L35 has been successfully added to your 
